Lilly Drops Commercialization Efforts For Yentreve
This article was originally published in The Pink Sheet Daily
Executive Summary
A year after withdrawing its NDA, Lilly gives up on a stress urinary incontinence indication for duloxetine.
You may also be interested in...
Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review
Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.